Thermo Fisher Scientific Oncomine Dx Target Test Gets Expanded Regulatory Approval in Japan

Feb 26, 2019

NEW YORK (GenomeWeb) – Thermo Fisher Scientific said today that Japan's Ministry of Health, Labor, and Welfare has granted expanded approval to its Oncomine Dx Target Test CDx System.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Menu

Thermo Fisher Scientific Oncomine Dx Target Test Gets Expanded Regulatory Approval in Japan

To read the full story....

Breaking News

NICE Guidance Recommends Amgen's Blincyto for ALL Patients in Remission

Japanese Regulators Approve Invivoscribe Assay as CDx for Daiichi Sankyo AML Drug

Resolution Bioscience, Janssen Partner to Develop CDx for Niraparib in Prostate Cancer

AstraZeneca, Merck's Lynparza, Myriad Genetics' BRCA Test Approved in Japan

Japan's National Cancer Center Adopts Qiagen Bioinformatics Platform for Precision Med Program

Roche's Rozlytrek Nets Japanese Approval in NTRK-Positive Pan Cancer Indication

A Novel Quality Improvement Model to Support Molecular Testing of Oncology Patients

What's Popular?

Next-Generation Sequencing of Pediatric Cancer Patients Could Transform Treatment Paradigms

Resolution Bioscience, Janssen Partner to Develop CDx for Niraparib in Prostate Cancer

Japan's National Cancer Center Adopts Qiagen Bioinformatics Platform for Precision Med Program

Japanese Regulators Approve Invivoscribe Assay as CDx for Daiichi Sankyo AML Drug

AstraZeneca, Merck's Lynparza, Myriad Genetics' BRCA Test Approved in Japan

Sponsorships